Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study goal is to conduct a randomized controlled trial to compare safety and accuracy of dosing based on clinical information including the clinical reason for your taking coumadin, your age, gender, your body surface area, and other medical conditions you may have with dosing estimated by a dosing calculator which adjusts for factors affecting coumadin dosing variability including genotypes for genes important in Coumadin metabolism and response. The hypothesis to be tested by this trial states that:when compared to patients managed with a best practices standard-of-care coumadin dosing regimen, patients randomized to coumadin dosing based on genetically programmed metabolic capacity and other known clinical and environmental factors affecting dose will: 1)show reduced risk of adverse events (using surrogate measures of such events); and 2)more rapidly achieve Coumadin dosing.
| Condition | Intervention |
|---|---|
|
Atrial Fibrillation Deep Venous Thrombosis Heart Valve Replacement Pulmonary Embolism |
Drug: Coumadin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing |
- weighted time in therapeutic range
- absolute deviation from clinically optimal dose
- time to stable dose in therapeutic target range
- warfarin related adverse drug events
- time to first INR above 4
| Estimated Enrollment: | 260 |
| Study Start Date: | June 2007 |
| Estimated Study Completion Date: | May 2008 |
The study goal is to conduct a randomized controlled trial to compare safety and accuracy of dosing based on clinical information including clinical reason for taking coumadin, your age, gender, your body surface area, and other medical conditions you may have and dosing with dosing estimated by a dosing calculator which adjusts for factors affecting coumadin dosing variability including genotypes for genes important in Coumadin metabolism and response. The hypothesis to be tested by this trial states that:when compared to patients managed with a best practices standard-of-care coumadin dosing regimen, patients randomized to coumadin dosing based on genetically programmed metabolic capacity and other known clinical and environmental factors affecting dose will: 1)show reduced risk of adverse events (using surrogate measures of such events); and 2)more rapidly achieve Coumadin dosing
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Caucasian male and female patients(including Hispanic white) greater than or equal to 40 years of age;
- Patients initiating coumadin therapy without a documented history of stabilized dose of coumadin therapy;
- Target INR of 2 to 3.5;
- Women of childbearing potential must use an effective method of birth control(e.g. condom,oral contraceptives, indwelling intrauterine device, abstinence.
Exclusion Criteria:
- Age less than 40 years;
- Patients of known Native American, Asian, or African descent;
- Patients with thrombocytopenia(platelet count<50x10 cells/ml);
- Patient has previously received coumadin and information on dosing of the patient is known at time of restarting coumadin;
- Patients with severe to moderate hepatic insufficiency (AST or ALT less than 2x the upper limit of normal;
- Clinical contraindication for coumadin therapy;
- Female patients with a positive pregnancy test or women who are breastfeeding
Contacts and Locations| Contact: Deborah J Hilgemann, Res. Coord. | 715-389-3774 ext same | hilgemann.deborah@marshfieldclinic.org |
| Contact: Sandra K Strey, Res. Coord. | 715-389-4030 ext same | strey.sandra@marshfieldclinic.org |
| United States, Wisconsin | |
| Third Wave Molecular Diagnostics | Not yet recruiting |
| Madison, Wisconsin, United States, 53719 | |
| Sub-Investigator: Amy Brower, PhD | |
| Marshfield Clinic | |
| Marshfield, Wisconsin, United States, 54449 | |
| Principal Investigator: | Michael Caldwell, Physician | Marshfield Clinic Research Foundation |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00484640 History of Changes |
| Other Study ID Numbers: | #RO1 HS 016335-01 |
| Study First Received: | June 4, 2007 |
| Last Updated: | June 8, 2007 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Vascular Diseases Lung Diseases Respiratory Tract Diseases Atrial Fibrillation Embolism Pulmonary Embolism Thrombosis |
Venous Thrombosis Venous Thromboembolism Pathologic Processes Embolism and Thrombosis Thromboembolism Warfarin Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013